Preclinical
April 17, 2023
AACR
ZW220, a novel NaPi2b-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
Hernández et al.
Preclinical
March 15, 2023 - March 16, 2023
World ADC London
ZW191: A Potential Best-in-Class TOPO1i ADC for Treatment of FRα-Expressing Solid Tumors
Sam Lawn
Zanidatamab
March 13, 2023
Nature Communications
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
Weisser et al.
Zanidatamab Zovodotin
February 22, 2023 - February 23, 2023
European Bispecific & Multispecific Antibody Congress
Design and Functional Characterization of Zanidatamab Zovodotin (ZW49), a HER2-targeting Biparatopic Antibody Drug Conjugate in Clinical Development
Stuart Barnscher
Zanidatamab
January 19, 2023 - January 21, 2023
ASCO GI
Zanidatamab + Chemotherapy as First line Treatment for HER2 expressing Metastatic Gastroesophageal Adenocarcinoma (mGEA)
Elimova et al.
Zanidatamab
December 6, 2022 - December 10, 2022
SABCS
Antitumor Activity of Zanidatamab with Palbociclib and Fulvestrant in HER2+ Hormone-Receptor Positive (HR+) Metastatic Breast Cancer
Escrivá-de-Romani et al.
Preclinical
December 5, 2022
Antibody Engineering & Therapeutics Conference
Novel IgG1 Cysteine Insertion Sites Enable Site-Specific Conjugation and Precise Control of Drug to Antibody Ratio
Das et al.
Zanidatamab
December 1, 2022
Lancet Oncology
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
Meric-Bernstam et al.
Preclinical
November 10, 2022
SITC
Optimization of purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs)
Garnett et al.
Preclinical
October 13, 2022
Cancer Cell
The therapeutic window of antibody drug conjugates: A dogma in need of revision
Colombo et al.
Zanidatamab Zovodotin
September 12, 2022
ESMO
Preliminary Results From a Phase 1 Study Using the Bispecific, Human Epidermal Growth Factor 2 (HER2)-targeting Antibody-drug Conjugate (ADC) Zanidatamab Zovodotin (ZW49) in Solid Cancers
Jhaveri et al.
Preclinical
September 9, 2022
World ADC San Diego
Zymeworks Topoisomerase 1 Inhibitor ADC Platform: From Concept to Pipeline
Barnscher et al.
